Earnings Feed
Start Free
Gossamer Bio, Inc.·4

Mar 20, 4:22 PM ET

Aranda Richard 4

4 · Gossamer Bio, Inc. · Filed Mar 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Gossamer Bio CMO Richard Aranda Receives Repriced Options

What Happened
Richard Aranda, Chief Medical Officer of Gossamer Bio (GOSS), had a group of outstanding stock options cancelled and simultaneously regranted (derivative transactions) as part of a one‑time option repricing effective March 19, 2026. The filing shows dispositions to the issuer totaling 2,348,118 option shares and corresponding grants of 2,348,118 repriced options. The new per‑share exercise price for the repriced options is $0.45. No cash purchase or open‑market sale of common stock is reported in this filing.

Key Details

  • Transaction date: March 19, 2026; Form 4 filed March 20, 2026 (timely).
  • Total options affected: 2,348,118 (sum of multiple dispositions and matching grants).
  • New exercise price after repricing: $0.45 per share (per footnote).
  • Shares owned after transaction: Not specified in the filing.
  • Footnotes: F1 — one‑time repricing reduced exercise price to $0.45; all other terms (including vesting and term) remain in effect. F2 — the regranted options vest per the original award agreements and require continued service to vest.
  • Transaction type: Derivative repricing (codes D = disposition to issuer; A = grant/acquisition of derivative), not a cash sale/purchase.

Context

  • This was an internal option repricing/regrant (administrative adjustment), not an open‑market buy or sale of common stock. Repricings are typically intended to adjust incentive compensation and do not by themselves indicate insider buying or selling of shares.

Insider Transaction Report

Form 4
Period: 2026-03-19
Gossamer Bio, Inc.GOSS
Aranda Richard
Chief Medical Officer
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−562,500→ 0 total
    Exercise: $2.88Exp: 2036-01-01→ Common Stock (562,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−572,000→ 0 total
    Exercise: $1.13Exp: 2035-03-03→ Common Stock (572,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−487,500→ 0 total
    Exercise: $0.97Exp: 2034-01-01→ Common Stock (487,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−162,500→ 0 total
    Exercise: $0.84Exp: 2033-11-19→ Common Stock (162,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−157,500→ 0 total
    Exercise: $1.21Exp: 2033-03-19→ Common Stock (157,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−157,500→ 0 total
    Exercise: $2.16Exp: 2032-12-06→ Common Stock (157,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−126,667→ 0 total
    Exercise: $1.36Exp: 2032-01-05→ Common Stock (126,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−20,000→ 0 total
    Exercise: $1.36Exp: 2031-06-21→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−40,000→ 0 total
    Exercise: $1.36Exp: 2031-02-25→ Common Stock (40,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−22,784→ 0 total
    Exercise: $1.36Exp: 2030-02-14→ Common Stock (22,784 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−9,167→ 0 total
    Exercise: $1.36Exp: 2029-12-23→ Common Stock (9,167 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−30,000→ 0 total
    Exercise: $1.36Exp: 2029-03-25→ Common Stock (30,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+562,500→ 562,500 total
    Exercise: $0.45Exp: 2036-01-01→ Common Stock (562,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+572,000→ 572,000 total
    Exercise: $0.45Exp: 2035-03-03→ Common Stock (572,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+487,500→ 487,500 total
    Exercise: $0.45Exp: 2034-01-01→ Common Stock (487,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+162,500→ 162,500 total
    Exercise: $0.45Exp: 2033-11-19→ Common Stock (162,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+157,500→ 157,500 total
    Exercise: $0.45Exp: 2033-03-19→ Common Stock (157,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+157,500→ 157,500 total
    Exercise: $0.45Exp: 2032-12-06→ Common Stock (157,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+126,667→ 126,667 total
    Exercise: $0.45Exp: 2032-01-05→ Common Stock (126,667 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+20,000→ 20,000 total
    Exercise: $0.45Exp: 2031-06-21→ Common Stock (20,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+40,000→ 40,000 total
    Exercise: $0.45Exp: 2031-02-25→ Common Stock (40,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+22,784→ 22,784 total
    Exercise: $0.45Exp: 2030-02-14→ Common Stock (22,784 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+9,167→ 9,167 total
    Exercise: $0.45Exp: 2029-12-23→ Common Stock (9,167 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+30,000→ 30,000 total
    Exercise: $0.45Exp: 2029-03-25→ Common Stock (30,000 underlying)
Footnotes (2)
  • [F1]Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
  • [F2]This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Signature
/s/ Jeff Boerneke, Attorney-in-Fact|2026-03-20

Documents

1 file
  • 4
    wk-form4_1774038115.xmlPrimary

    FORM 4